financetom
Business
financetom
/
Business
/
US accuses Visa of monopolizing debit card swipes
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US accuses Visa of monopolizing debit card swipes
Sep 26, 2024 1:22 AM

Sept 24 (Reuters) - The U.S. Department of Justice sued

Visa for alleged antitrust violations on Tuesday, accusing

one of the world's largest payment networks of suppressing

competition by threatening merchants with high fees and paying

off potential rivals.

(Reporting by Jody Godoy in New York)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Credo Technology Group Holding Insider Sold Shares Worth $5,640,261, According to a Recent SEC Filing
Credo Technology Group Holding Insider Sold Shares Worth $5,640,261, According to a Recent SEC Filing
Jun 10, 2025
03:51 AM EDT, 06/10/2025 (MT Newswires) -- Lip Bu Tan, Director, on June 05, 2025, sold 75,000 shares in Credo Technology Group Holding ( CRDO ) for $5,640,261. Following the Form 4 filing with the SEC, Tan has control over a total of 1,115,618 ordinary shares of the company, with 53,574 shares held directly and 1,062,044 controlled indirectly. SEC Filing:...
Jazz Pharmaceuticals Says Narcolepsy Drug Meets Primary Endpoint in Phase 4 Trial
Jazz Pharmaceuticals Says Narcolepsy Drug Meets Primary Endpoint in Phase 4 Trial
Jun 10, 2025
03:49 AM EDT, 06/10/2025 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) said late Monday its Xywav drug met its primary endpoint of change in mean 24-hour ambulatory systolic blood pressure in a phase 4 trial of patients with narcolepsy. Narcolepsy is a neurological sleep disorder that results in the inability to sleep continuously at night. The study also achieved...
Expanding missile threats and airspace closures are straining airlines
Expanding missile threats and airspace closures are straining airlines
Jun 10, 2025
* Conflict zones reducing available flight paths * Diversions, cancellations are a growing cost burden for airlines * Civil aviation spending more on security planning, data By Lisa Barrington, Shivansh Tiwary and Joanna Plucinska NEW DELHI, June 4 (Reuters) - Proliferating conflict zones are an increasing burden on airline operations and profitability, executives say, as carriers grapple with missiles and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved